Support

Contact Us

Privacy Policy

2020 © Healgen Scientific, LLC. All Rights Reserved. 

Follow Us

  • LinkedIn - White Circle
  • Facebook - White Circle

Heart Fatty Acid-Binding Protein (h-FABP) Rapid Detection Kit

Heart Fatty Acid-Binding Protein (h-FABP) Rapid Test is a rapid visual immunoassay for the qualitative presumptive detection of cardiac Heart fatty acid-binding protein (h-FABP) in human whole blood, serum, or plasma specimens. This kit is intended to be used as a screening method to aid in the diagnosis of myocardial infarction (MI).

 

Heart-type fatty acid binding protein (h-FABP) is known as mammary-derived growth inhibitor is a protein that in humans is encoded by the FABP3 gene. Heart-type Fatty Acid-Binding Protein (H-FABP) is a small cytoplasmic protein (15 kDa) released from cardiac myocytes following an ischemic episode. Like the nine other distinct FABPs that have been identified, H-FABP is involved in active fatty acid metabolism where it transports fatty acids from the cell membrane to mitochondria for oxidation. h-FABP is a sensitive biomarker for myocardial infarction and can be detected in the blood within one to three hours after the onset acute chest pain. The diagnostic potential of the biomarker H-FABP for heart injury was discovered in 1988 by Professor Jan Glatz (Maastricht, Netherlands) h-FABP is 20 times more specific to cardiac muscle than myoglobin, it is found at 10-fold lower levels in skeletal muscle than heart muscle and the amounts in the kidney, liver and small intestine are even lower again.

Features

Specifications

Ordering Information

Sources:

1. Phelan CM, Larsson C, Baird S, Futreal PA, Ruttledge MH, Morgan K, Tonin P, Hung H, Korneluk RG, Pollak MN, Narod SA (Dec 1996). "The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumors". Genomics 34 (1): 63–8.

2. Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ (October 1992). "Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man". Mol. Cell. Biochem. 116 (1–2): 155–62.

3. Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K (April 1991). "Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction". Clin. Biochem. 24 (2): 195–201.

4. Watanabe K, Wakabayashi H, Veerkamp JH, Ono T, Suzuki T (May 1993). "Immunohistochemical distribution of heart-type fatty acid-binding protein immunoreactivity in normal human tissues and in acute myocardial infarct". J. Pathol. 170 (1): 59–65.

5. Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp JH, van der Vusse GJ, Reneman RS (July 1988). "Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox". Biochim. Biophys. Acta 961 (1): 148–52.

6. Ghani F, Wu AH, Graff L, Petry C, Armstrong G, Prigent F, Brown M (May 2000). "Role of heart-type fatty acid-binding protein in early detection of acute myocardial infarction". Clin. Chem. 46 (5): 718–9.